APRE Aprea Therapeutics Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 26 March 2020 Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

   BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

2. 13 February 2020 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial

   BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ:APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53

3. 30 January 2020 Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation

   BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

4. 09 January 2020 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020

   BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

5. 09 December 2019 Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

   74% ORR, 66% CR rate in 24 evaluable MDS patientsMedian duration of follow-up is 6.4 months BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on

6. 09 December 2019 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

   88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients52% of evaluable MDS patients discontinued treatment

7. 14 November 2019 Aprea Therapeutics Reports Third Quarter 2019 Financial Results

   BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

8. 06 November 2019 Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting

   BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

9. 07 October 2019 Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

   BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor